Emerging biological therapies for the treatment of malignant pleural mesothelioma.

Davis, Alexander P; Kao, Steven C; Clarke, Stephen J; Boyer, Michael; Pavlakis, Nick

Davis, Alexander P; Kao, Steven C; Clarke, Stephen J; Boyer, Michael; Pavlakis, Nick.

Afiliação

Davis AP; Department of Medical Oncology, Chris O'Brien Lifehouse, Camperdown, Australia.
Kao SC; Department of Medical Oncology, Chris O'Brien Lifehouse, Camperdown, Australia.
Clarke SJ; Asbestos Disease Research Institute, Rhodes, Australia.
Boyer M; Sydney Medical School, The University of Sydney, Sydney, Australia.
Pavlakis N; Sydney Medical School, The University of Sydney, Sydney, Australia.

Expert Opin Emerg Drugs ; 26(2): 179-192, 2021 06.

Article em En | MEDLINE | ID: mdl-33945357

Assuntos

Imunoterapia/métodos; Mesotelioma Maligno/terapia; Neoplasias Pleurais/terapia; Terapia Biológica/métodos; Biomarcadores Tumorais/metabolismo; Humanos; Mesotelioma Maligno/imunologia; Neoplasias Pleurais/imunologia; Medicina de Precisão

Palavras-chave

Chimeric antigen receptor (CAR) T cells; dendritic cell therapy; immune checkpoint inhibitors; immunotherapy; malignant pleural mesothelioma (MPM); mesothelin; tumor treating fields

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Pleurais / Mesotelioma Maligno / Imunoterapia Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google